Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ampreloxetine for symptomatic neurogenic orthostatic hypotension in primary autonomic failure
2018-003289-15Phase 3Unknown
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Neurogenic Orthostatic Hypotension (nOH) comparing ampreloxetine with placebo (2 arms). Primary endpoint: Change from baseline in OHSA Question 1 at Week 4. Status: unknown.
02
Drugs
ampreloxetine
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on 2018-003289-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003289-15.